DexCom — Oct 24, 2024 release

“We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025.” 2024 Annual Guidance Dexcom is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: • Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth 2 ) • Non-GAAP Gross Profit Margin of approximately 63% • Non-GAAP Operating Margin of approximately 20% • Adjusted EBITDA Margin of approximately 29% 1 Third quarter 2024 organic revenue was $994.7 million and excludes $0.5 million of foreign exchange impact. Third quarter 2023 reported revenue included $8.0 million of non-CGM revenue subsequently divested in the following twelve months. 2 Organic growth excludes non-CGM revenue acquired or divested in the trailing twelve months, as well as the impact of foreign exchange. Dexcom's 2024 organic growth expectation excludes approximately $30 million of fiscal year 2023 revenue related to the divestiture of certain non-CGM assets. Commercial Leadership Update Dexcom also announced today that Teri Lawver, Executive Vice President and Chief Commercial Officer, will retire at the end of the year. She will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer. “I want to personally thank Teri for her strong leadership and dedication, as seen most